Skip to content
value.today

Quest Diagnostics Incorporated: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 3.7% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $27.8 B means free cash flow growing 14.3% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew 3.7% a year over the last three years.

Cash-flow value of the shares
$10.0 B
-64% against the market value
Value of the whole business
$15.3 B
before net debt
Value from after year 10
50%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-1.26%1.24%3.74%6.24%8.74%
8.15%-68%-57%-44%-28%-8%
9.15%-75%-66%-55%-42%-26%
10.15%-80%-73%-64%-53%-40%
11.15%-85%-78%-70%-61%-50%
12.15%-88%-82%-76%-67%-58%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Diagnostics and Research: $30.0 B to $68.8 B, median $35.6 BPrice to salesPrice to sales of Diagnostics and Research: $26.0 B to $88.4 B, median $59.9 BPrice to bookPrice to book of Diagnostics and Research: $19.5 B to $100.5 B, median $49.4 BCash-flow value$0 M$27.1 B$54.3 B$81.4 B$108.6 BMarket value $27.8 B

Your own DCF model

A full discounted-cash-flow model of Quest Diagnostics Incorporated, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times Quest Diagnostics Incorporated's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)The companyApplied toValue (25th to 75th)Companies
P/E30.2× / 35.9× / 69.4×24.6×net income $992 M$30.0 B to $68.8 B21
Price to sales2.4× / 5.4× / 8.0×2.4×revenue $11.0 B$26.0 B to $88.4 B36
Price to book2.7× / 6.9× / 14.0×3.9×book equity $7.2 B$19.5 B to $100.5 B34

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Quest Diagnostics Incorporated's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

26.2×

Now above its median of 21.7×, in the top quarter of its range; range 8.9× to 26.2× over 30 months.

0×7×13×20×26×2020202120222023202420252026P/E 26×Median 22×

Price to sales

2.4×

Now above its median of 1.9×, in the top quarter of its range; range 1.5× to 2.4× over 30 months.

0×1×1×2×2×2020202120222023202420252026Price to sales 2×Median 2×

Price to book

3.9×

Now above its median of 3.0×, in the top quarter of its range; range 2.6× to 3.9× over 30 months.

0×1×2×3×4×2020202120222023202420252026Price to book 4×Median 3×

as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$11.0 B$992 M$1.9 B$527 M$1.4 B$5.3 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$9.9 B$871 M$1.3 B$425 M$909 M$5.7 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$9.3 B$854 M$1.3 B$408 M$864 M$4.0 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$9.9 B$946 M$1.7 B$404 M$1.3 B$3.7 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$10.8 B$2.0 B$2.2 B$403 M$1.8 B$3.1 BSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$9.4 B$1.4 B$2.0 B$418 M$1.6 B$2.9 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $27.8 B on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.